New triple therapy offers hope for hard-to-treat leukemia patients
NCT ID NCT03661307
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 30 times
Summary
This study tests whether combining three drugs—quizartinib, decitabine, and venetoclax—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The trial includes 73 adults aged 60 or older who cannot have standard intensive chemotherapy, or whose cancer has returned. The goal is to find the safest dose and see how many patients achieve remission, but ongoing treatment is needed to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.